These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 24662946)

  • 41. Using antiubiquitin antibodies to probe the ubiquitination state within rhTRIM5α cytoplasmic bodies.
    Danielson CM; Hope TJ
    AIDS Res Hum Retroviruses; 2013 Oct; 29(10):1373-85. PubMed ID: 23799296
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry.
    Chatterji U; Bobardt MD; Gaskill P; Sheeter D; Fox H; Gallay PA
    J Biol Chem; 2006 Dec; 281(48):37025-33. PubMed ID: 17028189
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trafficking of some old world primate TRIM5α proteins through the nucleus.
    Diaz-Griffero F; Gallo DE; Hope TJ; Sodroski J
    Retrovirology; 2011 May; 8():38. PubMed ID: 21575157
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The cyclophilin A-binding loop of the capsid regulates the human TRIM5α sensitivity of nonpandemic HIV-1.
    Twizerimana AP; Becker D; Zhu S; Luedde T; Gohlke H; Münk C
    Proc Natl Acad Sci U S A; 2023 Nov; 120(48):e2306374120. PubMed ID: 37983491
    [TBL] [Abstract][Full Text] [Related]  

  • 45. TRIM5α and TRIM22 are differentially regulated according to HIV-1 infection phase and compartment.
    Singh R; Patel V; Mureithi MW; Naranbhai V; Ramsuran D; Tulsi S; Hiramen K; Werner L; Mlisana K; Altfeld M; Luban J; Kasprowicz V; Dheda K; Abdool Karim SS; Ndung'u T
    J Virol; 2014 Apr; 88(8):4291-303. PubMed ID: 24478420
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection.
    Wu X; Anderson JL; Campbell EM; Joseph AM; Hope TJ
    Proc Natl Acad Sci U S A; 2006 May; 103(19):7465-70. PubMed ID: 16648264
    [TBL] [Abstract][Full Text] [Related]  

  • 47. TRIM5alpha association with cytoplasmic bodies is not required for antiretroviral activity.
    Song B; Diaz-Griffero F; Park DH; Rogers T; Stremlau M; Sodroski J
    Virology; 2005 Dec; 343(2):201-11. PubMed ID: 16183097
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Binding of the rhesus TRIM5α PRYSPRY domain to capsid is necessary but not sufficient for HIV-1 restriction.
    Yang Y; Brandariz-Nuñez A; Fricke T; Ivanov DN; Sarnak Z; Diaz-Griffero F
    Virology; 2014 Jan; 448():217-28. PubMed ID: 24314652
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Homology-based identification of capsid determinants that protect HIV1 from human TRIM5α restriction.
    Maillard PV; Zoete V; Michielin O; Trono D
    J Biol Chem; 2011 Mar; 286(10):8128-8140. PubMed ID: 21169362
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibitory effect of human TRIM5alpha on HIV-1 production.
    Zhang X; Kondo M; Chen J; Miyoshi H; Suzuki H; Ohashi T; Shida H
    Microbes Infect; 2010 Sep; 12(10):768-77. PubMed ID: 20493962
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TRIM5α restriction affects clinical outcome and disease progression in simian immunodeficiency virus-infected rhesus macaques.
    Wu F; Ourmanov I; Riddick N; Matsuda K; Whitted S; Plishka RJ; Buckler-White A; Starost MF; Hirsch VM
    J Virol; 2015 Feb; 89(4):2233-40. PubMed ID: 25473059
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TRIM5alpharh expression restricts HIV-1 infection in lentiviral vector-transduced CD34+-cell-derived macrophages.
    Anderson J; Akkina R
    Mol Ther; 2005 Oct; 12(4):687-96. PubMed ID: 16081321
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of common human TRIM5alpha variants in HIV-1 disease progression.
    Goldschmidt V; Bleiber G; May M; Martinez R; Ortiz M; Telenti A;
    Retrovirology; 2006 Aug; 3():54. PubMed ID: 16925802
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.
    Stremlau M; Owens CM; Perron MJ; Kiessling M; Autissier P; Sodroski J
    Nature; 2004 Feb; 427(6977):848-53. PubMed ID: 14985764
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The antiviral spectra of TRIM5α orthologues and human TRIM family proteins against lentiviral production.
    Ohmine S; Sakuma R; Sakuma T; Thatava T; Takeuchi H; Ikeda Y
    PLoS One; 2011 Jan; 6(1):e16121. PubMed ID: 21264255
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TRIM5α does not affect simian immunodeficiency virus SIV(mac251) replication in vaccinated or unvaccinated Indian rhesus macaques following intrarectal challenge exposure.
    Fenizia C; Keele BF; Nichols D; Cornara S; Binello N; Vaccari M; Pegu P; Robert-Guroff M; Ma ZM; Miller CJ; Venzon D; Hirsch V; Franchini G
    J Virol; 2011 Dec; 85(23):12399-409. PubMed ID: 21917950
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Retroviral restriction factors TRIM5α: therapeutic strategy to inhibit HIV-1 replication.
    Zhang J; Ge W; Zhan P; De Clercq E; Liu X
    Curr Med Chem; 2011; 18(17):2649-54. PubMed ID: 21568899
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TRIM5alpha disrupts the structure of assembled HIV-1 capsid complexes in vitro.
    Black LR; Aiken C
    J Virol; 2010 Jul; 84(13):6564-9. PubMed ID: 20410272
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Caging the beast: TRIM5α binding to the HIV-1 core.
    Diaz-Griffero F
    Viruses; 2011 May; 3(5):423-8. PubMed ID: 21994740
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of novel TRIM5alpha variants, Gly110Arg and G176del, on the anti-HIV-1 activity and the susceptibility to HIV-1 infection.
    Nakajima T; Nakayama EE; Kaur G; Terunuma H; Mimaya JI; Ohtani H; Mehra N; Shioda T; Kimura A
    AIDS; 2009 Oct; 23(16):2091-100. PubMed ID: 19710594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.